The estimated Net Worth of Haig P. Bozigian is at least $30.2 Milión dollars as of 5 February 2021. Haig Bozigian owns over 4,546 units of Neurocrine Biosciences stock worth over $19,149,867 and over the last 17 years he sold NBIX stock worth over $6,240,840. In addition, he makes $4,781,000 as Chief Development Officer at Neurocrine Biosciences.
Sign up
Haig Bozigian NBIX stock SEC Form 4 insiders trading
Haig has made over 52 trades of the Neurocrine Biosciences stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 4,546 units of NBIX stock worth $528,836 on 5 February 2021.
The largest trade he's ever made was exercising 75,873 units of Neurocrine Biosciences stock on 5 March 2018 worth over $976,486. On average, Haig trades about 11,877 units every 42 days since 2008. As of 5 February 2021 he still owns at least 157,651 units of Neurocrine Biosciences stock.
You can see the complete history of Haig Bozigian stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Haig Bozigian biography
Dr. Haig P. Bozigian Ph.D. serves as Chief Development Officer of the Company. He was appointed Chief Development Officer in 2013 after having served as Senior Vice President of Pharmaceutical and Preclinical Development. Dr. Bozigian is responsible for all preclinical development, chemistry manufacturing and controls (CMC) and clinical pharmacology, and has led such functions since 2006. Dr. Bozigian joined Neurocrine Biosciences in 1997. With extensive expertise in CNS related new product development, Dr. Bozigian has participated in research and development for approximately 30 years. Prior to joining Neurocrine Biosciences, Dr. Bozigian served as Director of Pharmaceutical Development at Procyte Corporation, Associate Director of Pharmacokinetics and Drug Metabolism at Sphinx Pharmaceuticals Corporation and as a Clinical Pharmacokineticist at GlaxoSmithKline. Dr. Bozigian earned his B.S. in Microbiology from the University of Massachusetts, his M.S. in Pharmacodynamics and Toxicology from the University of Nebraska Medical Center, and earned his Ph.D. in Pharmaceutical Sciences from the University of Arizona.
What is the salary of Haig Bozigian?
As the Chief Development Officer of Neurocrine Biosciences, the total compensation of Haig Bozigian at Neurocrine Biosciences is $4,781,000. There are 4 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of $9,450,830.
How old is Haig Bozigian?
Haig Bozigian is 62, he's been the Chief Development Officer of Neurocrine Biosciences since 2012. There are 6 older and 17 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.
What's Haig Bozigian's mailing address?
Haig's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Insiders trading at Neurocrine Biosciences
Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
What does Neurocrine Biosciences do?
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
What does Neurocrine Biosciences's logo look like?
Complete history of Haig Bozigian stock trades at Neurocrine Biosciences
Neurocrine Biosciences executives and stock owners
Neurocrine Biosciences executives and other stock owners filed with the SEC include:
-
Kevin Gorman,
Chief Executive Officer, Director -
Matthew Abernethy,
Chief Financial Officer -
Eric Benevich,
Chief Commercial Officer -
Eiry Roberts,
Chief Medical Officer -
Haig Bozigian,
Chief Development Officer -
Kyle Gano,
Chief Business Development and Strategy Officer -
Dimitri Grigoriadis,
Chief Research Officer -
Dr. Kevin C. Gorman Ph.D.,
CEO & Director -
Dr. Eiry Wyn Roberts,
Chief Medical Officer -
Leslie Norwalk,
Independent Director -
Matthew C. Abernethy,
Chief Financial Officer -
Eric S. Benevich,
Chief Commercial Officer -
Kyle W. Gano,
Chief Bus. Devel. and Strategy Officer -
William Rastetter,
Independent Chairman of the Board -
Stephen Sherwin,
Independent Director -
Richard Pops,
Independent Director -
George Morrow,
Independent Director -
Gary Lyons,
Independent Director -
Todd Tushla,
Investor Relations -
Julie Cooke,
Chief Human Resource Officer -
Shalini Sharp,
Independent Director -
Darin Lippoldt,
Chief Legal Officer and Corporate Secretary -
Malcolm Lloyd-Smith,
Chief Regulatory Officer -
David Boyer,
Chief Corporate Affairs Officer -
Julie S. Cooke,
Chief HR Officer -
Darin M. Lippoldt,
Chief Legal Officer & Corp. Sec. -
Jane Sorensen,
Head of Investor Relations -
Dr. Jude Onyia Ph.D.,
Chief Scientific Officer -
Dr. Dimitri E. Grigoriadis,
Chief Research Officer -
Matt Abernethy,
Chief Financial Officer -
Corinne H Nevinny,
Director -
Christopher Flint O Brien,
Sr. VP & Chief Medical Officer -
Joseph A Mollica,
Director -
David Alexandre C Gros,
President & COO -
Alfred Sandrock,
Director -
Christine A Poon,
Director -
Wylie W Vale,
Director -
Timothy Coughlin,
VP and Chief Financial Officer -
Jensen Margaret E Valeur,
Senior VP and General Counsel -
Partners L P/Ilbiotechnolog...,
-
Johanna Mercier,
Director -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Henry Pan,
Executive VP and CMO -
Wendall Wierenga,
EVP, Research & Development -
Richard J Ranieri,
Sr. VP, Human Resources -
Thomas Mitchell W,
Director -
Ingrid Delaet,
Chief Regulatory Officer -
Paul W Hawran,
Executive VP and CFO -
Paul J Conlon,
Vice President Research (Biol) -
Lawrence Steinman,
Director -
John Saunders,
Vice President Research (Chem) -
Robert J Little,
SVP, Commercial Operations -
D Bruce Campbell,
Senior Vice President -
Jude Onyia,
Chief Scientific Officer